bioxcell熱銷產(chǎn)品--recombimab anti-mouse pd-l1 (b7-h1) (d265a)
產(chǎn)品描述：
10f.9g2™-cp001單克隆抗體是原始10f.9g2™單克隆抗體的重組嵌合型抗體?？勺兘Y(jié)構(gòu)域序列與原始10f.9g2™克隆號(hào)相同，但是恒定區(qū)序列已經(jīng)從大鼠igg2b變?yōu)樾∈骾gg1。10f.9g2™-cp001單克隆抗體在fc片段中也含有d265a突變，使其無(wú)法與內(nèi)源性fcγ受體結(jié)合。
10f.9g2™-cp001單克隆抗體與小鼠pd-l1（程序性死亡配體1，也稱為b7-h1或cd274）反應(yīng)。pd-l1是屬于ig超家族的b7家族的i型跨膜蛋白，分子量為40kda。pd-l1在t淋巴細(xì)胞、b淋巴細(xì)胞、nk細(xì)胞、樹(shù)突狀細(xì)胞以及ifnγ刺激的單核細(xì)胞、上皮細(xì)胞和內(nèi)皮細(xì)胞上表達(dá)。pd-l1與cd4和cd8胸腺細(xì)胞以及活化的t和b淋巴細(xì)胞和骨髓細(xì)胞上的受體pd-1結(jié)合。pd-l1與pd-1的結(jié)合導(dǎo)致抑制tcr介導(dǎo)的t細(xì)胞增殖和細(xì)胞因子產(chǎn)生。pd-l1被認(rèn)為在腫瘤免疫逃逸中起著重要作用。誘導(dǎo)的pd-l1表達(dá)在許多腫瘤中很常見(jiàn)，并導(dǎo)致腫瘤細(xì)胞對(duì)cd8+t細(xì)胞介導(dǎo)的裂解的抗性增加。在黑色素瘤的小鼠模型中，可以通過(guò)用阻斷pd-l1和pd-1之間相互作用的抗體進(jìn)行治療，暫時(shí)抑制腫瘤生長(zhǎng)。10f.9g2™單克隆抗體已被證明可以阻斷pd-l1和pd-1之間以及pd-l1和b7-1之間的相互作用（cd80）。
產(chǎn)品詳情：
產(chǎn)品名稱
recombimab anti-mouse pd-l1 (b7-h1) (d265a) /欣博盛生物
產(chǎn)品貨號(hào)
cp001
產(chǎn)品規(guī)格
1mg
反應(yīng)種屬
mouse
克隆號(hào)
10f.9g2™-cp001
同種型
mouse igg1(switched from rat igg2b)
免疫原
mouse cd274
實(shí)驗(yàn)應(yīng)用
in vivo pd-l1 blockade*
immunofluorescence*
immunohistochemistry (frozen)*
flow cytometry*
western blot*
*reported for the original rat igg2b 10f.9g2 antibody
產(chǎn)品形式
pbs, ph 7.0,contains no stabilizers or preservatives
純度
>95%, determined by sds-page
聚合
<5%, determined by sec
無(wú)菌處理
0.2 µm filtration
純化方式
protein a
分子量
150 kda
小鼠病原檢測(cè)
ectromelia/mousepox virus: negative
hantavirus: negative
k virus: negative
lactate dehydrogenase-elevating virus: negative
lymphocytic choriomeningitis virus: negative
mouse adenovirus: negative
mouse cytomegalovirus: negative
mouse hepatitis virus: negative
mouse minute virus: negative
mouse norovirus: negative
mouse parvovirus: negative
mouse rotavirus: negative
mycoplasma pulmonis: negative
pneumonia virus of mice: negative
polyoma virus: negative
reovirus screen: negative
sendai virus: negative
theiler’s murine encephalomyelitis: negative
保存條件
抗體原液保存在4°c，不能冷凍保存。
推薦抗體稀釋液
invivopure ph 7.0 dilution buffer（貨號(hào)ip0070）
該產(chǎn)品自上市已被多篇sci文獻(xiàn)引用，品質(zhì)有保證，以下是部分已發(fā)表的文獻(xiàn)引用：
應(yīng)用
文章
體內(nèi)pd-l1阻斷
(in vivo pd-l1 blockade)
1.grasselly, c., et al. (2018). 'the antitumor activity of combinations of cytotoxic
chemotherapy and immune checkpoint inhibitors is model-dependent' front
immunol 9: 2100.
2.stathopoulou, c., et al. (2018). 'pd-1 inhibitory receptor downregulates asparaginyl
endopeptidase and maintains foxp3 transcription factor stability in induced regulatory
t cells' immunity 49(2): 247-263 e247.
3.jaworska, k., et al. (2015). 'both pd-1 ligands protect the kidney from ischemia
reperfusion injury' j immunol 194(1): 325-333.
4.kim, j., et al. (2015). 'memory programming in cd8(+) t-cell differentiation is
intrinsic and is not determined by cd4 help' nat commun 6: 7994.
5.zander, r. a., et al. (2015). 'pd-1 co-inhibitory and ox40 co-stimulatory crosstalk
regulates helper t cell differentiation and anti-plasmodium humoral immunity' cell
host microbe 17(5): 628-641.
體內(nèi)pd-l1阻斷，流式細(xì)胞術(shù)
(in vivo pd-l1 blockade, flow
cytometry)
1.aloulou, m., et al. (2016). 'follicular regulatory t cells can be specific for the
immunizing antigen and derive from naive t cells' nat commun 7: 10579.
2.ngiow, s. f., et al. (2015). 'a threshold level of intratumor cd8+ t-cell pd1
expression dictates therapeutic response to anti-pd1' cancer res 75(18): 3800-3811.
3.rutigliano, j. a., et al. (2014). 'highly pathological influenza a virus infection is
associated with augmented expression of pd-1 by functionally compromised
virus-specific cd8+ t cells' j virol 88(3): 1636-1651.
體內(nèi)pd-l1阻斷，免疫熒光
(in vivo pd-l1 blockade,
immunofluorescence)
1.willimsky, g., et al. (2013). 'virus-induced hepatocellular carcinomas cause
antigen-specific local tolerance' j clin invest 123(3): 1032-1043.
免疫組織化學(xué)（冷凍），免疫熒光
(immunohistochemistry (frozen),
immunofluorescence)
1.riella, l. v., et al. (2011). 'essential role of pdl1 expression on nonhematopoietic
donor cells in acquired tolerance to vascularized cardiac allografts' am j transplant
11(4): 832-840.
更多產(chǎn)品詳情請(qǐng)聯(lián)系bioxcell中國(guó)授權(quán)代理——欣博盛生物